Related Experiment Video
Updated: Mar 12, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
13.4K
New Treatment Options for Osteosarcoma - Inactivation of Osteosarcoma Cells by Cold Atmospheric Plasma
Denis Gümbel1,2, Nadine Gelbrich3, Martin Weiss4
1Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University of Medicine Greifswald, Greifswald, Germany denis.guembel@uni-greifswald.de.
Anticancer Research
|October 30, 2016
Summary
Cold atmospheric plasma significantly reduced human osteosarcoma cell proliferation. This treatment induced apoptosis by increasing p53 expression and activating its phosphorylation, offering a potential new cancer therapy.
Area of Science:
- Biophysics
- Biochemistry
- Oncology
Background:
- Cold atmospheric plasma (CAP) demonstrates anti-tumor properties, inhibiting cancer cell growth and inducing cell death.
- Osteosarcoma is a primary bone cancer with significant mortality, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the impact of CAP on human osteosarcoma cell proliferation.
- To elucidate the cellular mechanisms underlying CAP's effects on these cancer cells.
Main Methods:
- Human osteosarcoma cell lines (U2-OS, MNNG/HOS) were exposed to CAP.
- Cell proliferation was quantified using standard cell culture assays.
- Protein expression of p53 and phospho-p53 was analyzed via Western blotting.
- Nuclear morphology was assessed using 4',6-diamidino-2-phenylindole (DAPI) staining.
Main Results:
- CAP treatment reduced osteosarcoma cell proliferation by up to 66%.
- A significant increase in p53 (2.3-fold) and phospho-p53 (4.5-fold) protein expression was observed.
- DAPI staining revealed characteristic apoptotic nuclear condensation in treated cells.
Conclusions:
- CAP effectively inhibits osteosarcoma cell proliferation in vitro.
- The observed anti-proliferative effects are mediated by the induction of apoptosis, evidenced by increased p53 levels and nuclear changes.
- CAP represents a promising preclinical therapeutic approach for osteosarcoma.
